Key Points
- Artivion SVP Jean Holloway sold 977 shares at an average price of $28.49, generating $27,834.73. She retained 184,118 shares, and her ownership declined by 0.53%.
- Artivion reported quarterly revenue of $125.76 million, exceeding analysts’ $119.99 million estimate, and posted EPS of $0.13. Analysts project full-year EPS of $0.45.
- Wall Street maintains a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $44.67; institutional investors own 86.37% of the company.
Artivion, Inc. (NYSE:AORT - Get Free Report) SVP Jean Holloway sold 977 shares of the firm's stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $28.49, for a total transaction of $27,834.73. Following the transaction, the senior vice president directly owned 184,118 shares in the company, valued at approximately $5,245,521.82. This represents a 0.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
Artivion Price Performance
Shares of Artivion stock opened at $28.77 on Thursday. The company has a quick ratio of 2.51, a current ratio of 3.47 and a debt-to-equity ratio of 0.82. The stock has a market capitalization of $1.40 billion, a price-to-earnings ratio of -410.94 and a beta of 1.25. Artivion, Inc. has a twelve month low of $19.16 and a twelve month high of $48.25. The company has a 50-day simple moving average of $23.95 and a two-hundred day simple moving average of $30.71.
Artivion (NYSE:AORT - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter. Artivion had a negative net margin of 0.67% and a positive return on equity of 6.07%. The firm had revenue of $125.76 million for the quarter, compared to analyst estimates of $119.99 million. Analysts forecast that Artivion, Inc. will post 0.45 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently issued reports on the company. Canaccord Genuity Group set a $39.00 price target on Artivion in a research report on Friday, August 7th. Wall Street Zen cut Artivion from a "buy" rating to a "hold" rating in a report on Saturday, April 25th. Stifel Nicolaus set a $45.00 target price on Artivion in a research report on Monday, June 1st. Citizens Jmp reduced their target price on Artivion from $53.00 to $48.00 and set a "market outperform" rating on the stock in a report on Friday, May 8th. Finally, Weiss Ratings lowered Artivion from a "sell (d+)" rating to a "sell (d-)" rating in a report on Tuesday. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Artivion has a consensus rating of "Moderate Buy" and an average price target of $44.67.
Check Out Our Latest Research Report on AORT
Institutional Trading of Artivion
Institutional investors and hedge funds have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Artivion during the 3rd quarter worth approximately $27,000. Rockefeller Capital Management L.P. increased its stake in Artivion by 150.0% in the fourth quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company's stock valued at $30,000 after acquiring an additional 399 shares during the last quarter. Larson Financial Group LLC raised its position in Artivion by 148.5% during the fourth quarter. Larson Financial Group LLC now owns 942 shares of the company's stock valued at $43,000 after purchasing an additional 563 shares in the last quarter. Smartleaf Asset Management LLC raised its position in Artivion by 47.7% during the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company's stock valued at $52,000 after purchasing an additional 538 shares in the last quarter. Finally, KBC Group NV bought a new stake in Artivion during the fourth quarter worth $65,000. Institutional investors own 86.37% of the company's stock.
Artivion Company Profile
(
Get Free Report)
Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.
Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
